In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

Source: 
Stat
snippet: 

 It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.